Evidence map›Paper›PMID 33299526›Full record

ReviewOxidative medicine and cellular longevity2020

Secondary Metabolites with Antioxidant Activities for the Putative Treatment of Amyotrophic Lateral Sclerosis (ALS): "Experimental Evidences".

Jamire M Silva, Michelangela S C Nobre, Sonaly L Albino, Lucas L Lócio, Agnis P S Nascimento, Luciana Scotti, Marcus T Scotti, João A Oshiro-Junior, Maria C A Lima, Francisco J B Mendonça-Junior and 1 more

Open access · hybridAbstract readReview
In one paragraph

Review in Oxidative medicine and cellular longevity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. NADBiomedicines · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Jamire M SilvaPostgraduate Program in Pharmaceutical Sciences-PPGCF, Department of Pharmacy, Federal University of Pernambuco, 50670-901 Recife PB, Brazil.
Michelangela S C NobrePostgraduate Program in Pharmaceutical Sciences-PPGCF, Department of Pharmacy, Federal University of Pernambuco, 50670-901 Recife PB, Brazil.
Sonaly L AlbinoDrug Development and Synthesis Laboratory, Department of Pharmacy, State University of Paraiba, 58429-500 Campina Grande PB, Brazil.
Lucas L LócioDrug Development and Synthesis Laboratory, Department of Pharmacy, State University of Paraiba, 58429-500 Campina Grande PB, Brazil.
Agnis P S NascimentoDrug Development and Synthesis Laboratory, Department of Pharmacy, State University of Paraiba, 58429-500 Campina Grande PB, Brazil.
Luciana ScottiLaboratory of Cheminformatics, Program of Natural and Synthetic Bioactive Products, Federal University of Paraiba, João Pessoa PB, Brazil.
Marcus T ScottiLaboratory of Cheminformatics, Program of Natural and Synthetic Bioactive Products, Federal University of Paraiba, João Pessoa PB, Brazil.
João A Oshiro-JuniorPostgraduate Program in Pharmaceutical Sciences-PPGCF, Department of Pharmacy, State University of Paraiba, 58429-500 Campina Grande PB, Brazil.
Maria C A LimaPostgraduate Program in Pharmaceutical Sciences-PPGCF, Department of Pharmacy, Federal University of Pernambuco, 50670-901 Recife PB, Brazil.
Francisco J B Mendonça-JuniorLaboratory of Synthesis and Drug Delivery, Department of Biological Sciences, State University of Paraiba, 58071-160 João Pessoa PB, Brazil.ORCID https://orcid.org/0000-0003-3588-833X
Ricardo O MouraDrug Development and Synthesis Laboratory, Department of Pharmacy, State University of Paraiba, 58429-500 Campina Grande PB, Brazil.
Universidade Estadual da Paraíba · BRUniversidade Federal da Paraíba · BRUniversidade Federal de Pernambuco · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disorder that is characterized by progressive loss of the upper and lower motor neurons at the spinal or bulbar level. Oxidative stress (OS) associated with mitochondrial dysfunction and the deterioration of the electron transport chain are factors that contribute to neurodegeneration and perform a potential role in the pathogenesis of ALS. Natural antioxidant molecules have been proposed as an alternative form of treatment for the prevention of age-related neurological diseases, in which ALS is included. Researches support that regulations in cellular reduction/oxidation (redox) processes are being increasingly implicated in this disease, and antioxidant drugs are aimed at a promising pathway to treatment. Among the strategies used for obtaining new drugs, we can highlight the isolation of secondary metabolite compounds from natural sources that, along with semisynthetic derivatives, correspond to approximately 40% of the drugs found on the market. Among these compounds, we emphasize oxygenated and nitrogenous compounds, such as flavonoids, coumarins, and alkaloids, in addition to the fatty acids, that already stand out in the literature for their antioxidant properties, consisting in a part of the diets of millions of people worldwide. Therefore, this review is aimed at presenting and summarizing the main articles published within the last years, which represent the therapeutic potential of antioxidant compounds of natural origin for the treatment of ALS.

Indexed as

Amyotrophic Lateral SclerosisAnimalsAntioxidantsDisease Models, AnimalHumansMotor NeuronsOxidative StressSecondary MetabolismAntioxidants

Identifiers

PMID33299526
PMCPMC7707995
OpenAlexW3108335720

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.